Possible side effects of drugs in elderly patients with chronic obstructive pulmonary disease and comorbidity


Cite item

Full Text

Abstract

The papers gives data on the positive effects and adverse reactions of drugs used to treat chronic obstructive pulmonary disease (COPD) and its comorbidity, first of all cardiovascular disease. The authors present alternative points of views based on both the data available in the literature and their findings. They propose to modify pharmacotherapy for COPD in the presence of comorbidity in patients of old age groups.

About the authors

F Т Malykhin

V A Baturin

References

  1. Глобальная стратегия диагностики, лечения и профилактики хронической обструктивной болезни легких (пересмотр 2011 г.). Пер. с англ. Под ред. Белевского А.С. М.: Российское респираторное общество; 2012.
  2. Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. Белевский А.С., Лещенко И.В., Мещерякова Н.Н., Овчаренко С.И., Шмелев Е.И. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. Пульмонология. 2014;3:15-54.
  3. GOLD. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. Update 2014.
  4. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA Jr, Enright PL, Kanner RE, O’Hara P. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 The Lung Health Study. JAMA. 1994;272:1497-1505.
  5. Куценко М.А., Чучалин А.Г. Парадигма коморбидности: синтропия ХОБЛ и ИБС. Русский медицинский журнал. 2014;5:389-392.
  6. Caughey GE, Vitry AI, Gilbert AL, Roughead EE. Prevalence of comorbidity of chronic diseases in Australia. BMC Public Health. 2008;8:221-233.
  7. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory Biomarkers and Comorbidities in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2012;186(10):982-988. doi: 10.1164/rccm.201206-1113oc.
  8. Sidney S, Sorel M, Quesenberry CPJ, DeLuise C, Lanes S, Eisner MD. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest. 2005;128:2068-2075.
  9. Holguin F, Folch E, Redd SC, Mannino DM. Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest. 2005;128(4):2005-2011.
  10. Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Ostergren J, Michelson EL, Pocock SJ, Maggioni AP, McMurray JJ; CHARM Investigators and Committees. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010;12:557-565. doi: 10.1093/eurjhf/hfq040.
  11. Buhl R, Dunn LJ, Disdier C, Lassen C, Amos C, Henley M, Kramer B; INTENSITY study investigators. INTENSITY study investigators. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J. 2011;38(4):797-803. doi: 10.1183/09031936.00191810.
  12. Лазебник Л.Б., Михайлова З.Ф. Особенности фармакотерапии сочетанной патологии у пожилых больных с хронической обструктивной болезнью легких. Consilium Medicum. Пульмонология 2005;7(12):996-1000.
  13. Huerta C, Lanes SF, García Rodríguez LA. Respiratory Medications and the Risk of Cardiac Arrhythmias. Epidemiology. 2005;16(3):360-366.
  14. Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respiratory J. 2011;37:273-279. doi: 10.1183/09031936.00045810.
  15. Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002;121(3):846-851.
  16. Calverley PMA, Anderson JA, Celli B. Cardiovascular events in patients with COPD: TORCH Study results. Thorax. 2010;65:719-725. doi: 10.1136/thx.2010.136077.
  17. Nguyen LP, Omoluabi O, Parra S, Frieske JM, Clement C, Ammar-Aouchiche Z, Ho SB, Ehre C, Kesimer M, Knoll BJ, Tuvim MJ, Dickey BF, Bond RA. Chronic exposure to β-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008;38:256-262.
  18. Малыхин Ф.Т. Показатели β-адренорецепции у пожилых больных с обострением хронического обструктивного бронхита. ВестникРУДН. 2012;1:43-45.
  19. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium — the FDA’s conclusions. N Engl J Med. 2010;363:1097-1099.
  20. Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, Gil EG. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013;10(4):511-522. doi: 10.3109/15412555.2013.814626.
  21. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Cur Opin Pulmon Med. 2010;16:97-105.
  22. Anthonisen NR, Connett JE, Enright PL, Manfreda J. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002;166:333-339.
  23. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium I chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.
  24. Chong J, Karner C, Poole P. Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease. Cochrane Database SystRev. 2012;9:CD009157.
  25. Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:1439-1450.
  26. Celli B, Decramer M, Kesten S, Liu D, Mehra S, Tashkin DP; UPLIFT Study Investigators. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir CritCare Med. 2009;180:948-955. doi: 10.1164/rccm.200906-0876oc.
  27. Oba Y, Zaza T, Thameem DM. Safety, tolerability, and risk benefit analysis of tiotropium in COPD. Int J COPD. 2008;3:575-584.
  28. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomized controlled trials. BMJ. 2011;342:d3215.
  29. Lipworth BJ, Short PM. Explaining differential effects of tiotropium on mortality in COPD. Thorax. 2013;68(6):589-590.
  30. Wise RA, Anzueto A, Cotton D, Dahl R, Dahl R, Devins T, Disse B, Dusser D, Joseph E, Kattenbeck S, Koenen-Bergmann M, Pledger G, Calverley P; TIOSPIR Investigators. Tiotropium Respimat Inhaler and the Risk of Death in COPD. N Engl J Med. 2013;369:1491-1501. doi: 10.1056/nejmoa1303342.
  31. Beeh KM, Singh D, Di Scala L, Drollmann A. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Int J Chron Obstruct Pulmon Dis. 2012;7:503-513.
  32. Малыхин Ф.Т. Сложившаяся практика бронхолитической терапии при хроническом обструктивном бронхите. Клиническая фармакологияи терапия. 2010;6:130-132.
  33. Ram FS. Use of theophylline in chronic obstructive pulmonary disease: examining the evidence. Curr Opin Pum Med. 2006;12:132-139.
  34. White WB, Cook GE, Kowey PR, Calverley PM, Bredenbröker D, Goehring UM, Zhu H, Lakkis H, Mosberg H, Rowe P, Rabe KF. Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD. Chest. 2013;144(3):758-765. doi: 10.1378/chest.12-2332.
  35. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011;163:53-67.
  36. Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med. 2009;4(3):115-123.
  37. Клиническая фармакокинетика: теоретические, прикладные и аналитические аспекты. Под ред. Кукеса В.Г. М.: ГЭОТАР-Медиа; 2009.
  38. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J. 2012;33:1787-1847. doi: 10.1093/eurheartj/ehs104.
  39. Малыхин Ф.Т., Визель А.А., Визель И.Ю. Применение мукоактивных лекарственных средств в практике терапевта. Архивъ внутреннеймедицины. 2013;5:10-15.
  40. Calverley PM, Stockley RA, Seemungal TA, Hagan G, Willits LR, Riley JH, Wedzicha JA; Investigating New Standards for Prophylaxis in Reduction of Exacerbations (INSPIRE) Investigators. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139:505-512. doi: 10.1378/chest.09-2992.
  41. Ferguson GT, Calverley PM, Anderson JA, Jenkins CR, Jones PW, Willits LR, Yates JC, Vestbo J, Celli B. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest. 2009;136:1456-1465. doi: 10.1378/chest.08-3016.
  42. Hawkins NM, Petrie MC, Macdonald MR, Jhund PS, Fabbri LM, Wikstrand J, McMurray JJ. Heart failure and chronic obstructive pulmonary disease. The quandary of β-blockers and β-agonists. J Am Coll Cardiol. 2011;57:2127-2138. doi: 10.1016/j.jacc.2011.02.020.
  43. Козлова Л.И., Айсанов З.Р., Чучалин А.Г. В чем опасность длительного применения бета-блокаторов у больных ишемической болезнью сердца с сопутствующей хронической обструктивной болезнью легких. Терапевтический архив. 2005;3:18-23.
  44. Mainguy V, Girard D, Maltais F, Saey D, Milot J, Sénéchal M, Poirier P, Provencher S. Effect of bisoprolol on respiratory function and exercise capacity in chronic obstructive pulmonary disease. Am J Cardiol. 2012;110(2):258-263. doi: 10.1016/j.amjcard.2012.03.019.
  45. Rutten FH, Zuithoff NPA, Hak E, Grobbee DE, Hoes AW. β-Blockers may reduce mortality and risk of exacerbations of patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887. doi: 10.1001/archinternmed.2010.112.
  46. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ. Effect of β-blockers in treatment of chronic obstructive pulmonary disease. Br Med J. 2011;342:d2549. doi: 10.1136/bmj.d2549.
  47. Etminan M, Jafari S, Carleton B, FitzGerald JM. β-Blocker use and COPD mortality: a systematic review and meta-analysis. BMC PulmMed. 2012;12:48. doi: 10.1186/1471-2466-12-48.
  48. Freemantle N, Urdahl H, Eastaugh J, Hobbs FD. What is the place of β-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation. Prog Cardiovasc Dis. 2002;44:243-250.
  49. Fox K, Garcia MAA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL; Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology; ESC Committee for Practice Guidelines (CPG). Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006;27:1341-1381.
  50. Goldberger JJ, Bonow RO, Cuffe M, Dyer A, Rosenberg Y, O’Rourke R, Shah PK, Smith SC Jr; PACE-MI Investigators. β-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. AmHeart J. 2010;160:435-442. doi: 10.1016/j.ahj.2010.06.023.
  51. Dransfield M, Rowe S, Johnson J, Bailey WC, Gerald LB. Use of β-blockers and the risk of death in hospitalized patients with acute exacerbations of COPD. Thorax. 2008;63:301-305.
  52. van Gestel YRBM, Hoeks SE, Sin DD, Welten GM, Schouten O, Witteveen HJ, Simsek C, Stam H, Mertens FW, Bax JJ, van Domburg RT, Poldermans D. Impact of cardioselective β-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008;178:695-700. doi: 10.1164/rccm.200803-384oc.
  53. Черняк Б.А., Трофименко И.Н. Лекарственно-индуцированные поражения легких. Медицина неотложных состояний. 2010;4(29):16-21.
  54. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006;47:2554-2560.
  55. Andreas S, Herrmann-Lingen C, Raupach Τ, Lüthje L, Fabricius JA, Hruska N, Körber W, Büchner B, Criée CP, Hasenfuss G, Calverley P. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial. Eur Respir J. 2006;27:972-979.
  56. Кузнецов О.О., Михайлова З.Ф. Хронический кашель у пожилых пациентов с нормальной рентгенограммой легких. Consilium Medicum. 2007;12:18-24.
  57. Dart RA, Gollub S, Lazar J, Nair C, Schroeder D, Woolf SH. Treatment of Systemic Hypertension in Patients With Pulmonary Disease COPD and Asthma. Chest. 2003;123(1):222-243.
  58. Dobler CC, Wong KK, Marks GB. Associations between statins and COPD: a systematic review. BMC Pulm Med. 2009;9:32.
  59. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207. doi: 10.1056/nejmoa0807646.
  60. Walsh GM. Defective apoptotic cell clearance in asthma and COPD: a new drug target for statins? Trends Pharmacol Sci. 2008;29:6-11.
  61. Lee JH, Lee DS, Kim EK, Choe KH, Oh YM, Shim TS, Kim SE, Lee YS, Lee SD. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005;172:987-993.
  62. Keddissi JI, Yuonis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT.The use of statins and lung function in current and former smokers. Chest. 2007;132:1764-1771.
  63. Alexeeff SE, Litonjua AA, Sparrow D, Vokonas PS, Schwartz J. Statin use reduces decline in lung function: VA Normative Ageing Study. Am JRespir Crit Care Med. 2007;176:742-747.
  64. Janda S, Park K, FitzGerald JM, Etminan M, Swiston J. Statins in COPD. A systematic review. Chest. 2009;136:734-743. doi: 10.1378/chest.09-0194.
  65. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomized, double-blind, placebo-controlled trial. Lancet. 2008;372:1231-1239. doi: 10.1016/s0140-6736(08)61240-4.
  66. Карпов Ю.А., Сорокин Е.В. Особенности лечения артериальной гипертонии при хронических обструктивных заболеваниях легких. Русский медицинский журнал. 2003;19:1048-1051.
  67. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-2219. doi: 10.1097/01.hjh.0000431740.32696.cc.
  68. Кукес В.Г., Остроумова О.Д., Стародубцев А.К. Современный взгляд на клинические и фармакологические особенности антагонистов кальция. Качественная клиническая практика. 2005;1:97-104.
  69. Zhang J, Zhao G, Yu X, Pan X. Intravenous diuretic and vasodilator therapy reduce plasma brain natriuretic peptide levels in acute exacerbation of chronic obstructive pulmonary disease. Respirology. 2012;17:715-720. doi: 10.1111/j.1440-1843.2012.02162.x.
  70. Agostoni P, Magini A, Andreini D, Contini M, Apostolo A, Bussotti M, Cattadori G, Palermo P. Spironolactone improves lung diffusion in chronic heart failure. Eur Heart J. 2005;26:159-164.
  71. Aronow W.S. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail. 2003;9:142-147.
  72. Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания Часть I. ХОБЛ и поражения сердечно-сосудистой системы. Русский медицинский журнал. 2008;2(16):58-65.
  73. Shrikrishna D, Patel M, Tanner RJ, Seymour JM, Connolly BA, Puthucheary ZA, Walsh SL, Bloch SA, Sidhu PS, Hart N, Kemp PR, Moxham J, Polkey MI, Hopkinson NS. Quadriceps wasting and physical inactivity in patients with COPD. Eur Respir J. 2012;40:1115-1122. doi: 10.1183/09031936.00170111.
  74. Батурин В.А., Щетинин Е.В., Малыхин Ф.Т. Состав микроорганизмов, выделяемых из мокроты у больных с инфекциями нижних дыхательных путей, и их чувствительность к антибактериальным средствам в зависимости от возраста пациентов, диагноза и предшествующего лечения. Профилактическая и клиническая медицина. 2012;2(43):48-51.
  75. Sabit R, Bolton CE, Edwards PH, Pettit RJ, Evans WD, McEniery CM, Wilkinson IB, Cockcroft JR, Shale DJ.Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:1259-1265.
  76. Малыхин Ф.Т., Батурин В.А., Хугаева А.Н. Анализ клинической практики фармакотерапии у пациентов с хронической обструктивной патологией с учетом коморбидных заболеваний. Ученые записки Орловского гос. университета. 2014;7(63): 70-71.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies